CMIC and AccuRna Hosted Webinar Series on Frontier of mRNA Drug Discovery
CMIC HOLDINGS Co., Ltd.
AccuRna Inc.
CMIC and AccuRna Hosted Webinar Series on Frontier of mRNA Drug Discovery
-Experts from Moderna, BioNTech and Japan Academia Presented-
Tokyo- August 26, 2020 – CMIC HOLDINGS Co., Ltd. (CMIC) and AccuRna Inc. (AccuRna) jointly held a series of webinars on messenger RNA (mRNA) medicines, Frontier of mRNA Drug Discovery, on July 14 and 28, 2020. More than 450 attendees from the pharmaceutical biotech companies and academia joined to learn and discuss about the therapeutic potential and expectations for development of mRNA medicines. It will further facilitate global collaboration and help accelerate mRNA drug development.
In the two webinars, experts from Japanese academia, Tokyo Medical and Dental University and the University of Tokyo, as well as global leading mRNA technology companies, Moderna, Inc. (the US) and BioNTech RNA Pharmaceuticals GmbH (Germany), provided up-to-date information on the basics of mRNA medicine and its clinical applications in view of infectious diseases and cancer immunotherapy. Latest information on a vaccine candidate for COVID-19 was mentioned by BioNTech utilizing its unique mRNA technology.
“We believe the two webinars brought leading-edge information in mRNA from both technology and clinical outcomes points of view.” said Keiko Oishi, President and COO of CMIC HOLDINGS Co., Ltd. “The globally renowned top experts in mRNA research provided lectures that surely promotes further communication and networking among academia and pharma/bio industries for mRNA medicines. CMIC group, as the first and largest clinical CRO in Japan with global footprint, will provide utmost support for non-clinical and clinical development in mRNA medicines, utilizing our services across the entire drug development value chain to meet our customers’ needs.”
“In the webinars, drug delivery system (DDS) were highlighted and DDS technology is indeed a key for successful mRNA medicines.” said Shiro Akinaga, President & CEO of AccuRna Inc. “We appreciate that the lectures enhanced broader potential of mRNA medicines in therapeutic applications, and this should further activate collaborations among academia and the industries.”
For more details, please visit our on-demand recording site for the two webinars:
July 14; Prophylactic and Therapeutic Applications of mRNA Technology for Infectious Diseases
Prof. Keiji Itaka (Tokyo Medical and Dental University)
Present status and future perspective on mRNA therapy
Dr. James Thompson (Moderna)
mRNA Technology for Infectious Diseases: Therapeutic Applications and Vaccine Development
July 28; Cancer treatment using mRNA and its future prospects
Prof. Kazuhiro Kakimi (The University of Tokyo)
mRNA-based Cancer Vaccine
Dr. Christoph Kröner (BioNTech)
Therapeutics against cancer and beyond using messenger RNA
■About CMIC Group
CMIC Group was founded in 1992 as the first Contract Research Organization (CRO) in Japan. Today CMIC Group is the largest clinical CRO in Japan with global footprint, providing comprehensive services in drug development, clinical site management, clinical to commercial GMP manufacturing, regulatory consulting and contract sales & marketing solutions. We can help pharmaceutical, biotech and medical device companies to enter Japan market, to conduct clinical trials in Asia, or to bridge drug development and manufacturing needs in the US, Europe, Japan and broader Asia. CMIC Group has over 7,000 employees and 25 sites globally.
■About AccuRna Inc.
AccuRna Inc. has established in December 2015 with a mission to achieve the practical use of the “RNA delivery system”, which is the research result of Prof. Kazunori Kataoka, Professor Emeritus of The University of Tokyo, Director general of Innovation Center of NanoMedicine Kawasaki Institute of Industrial Promotion. The goal of the company is to provide new nucleic acid medicine to patients suffering from underserved disease with high unmet needs through our internal development effort on pipeline based on aforementioned proprietary platform technology and external collaboration by applying these platform technologies to nucleic acid drug owned by our partners. AccuRna will be merged with NanoCarrier Co., Ltd. as of September 1, 2020 and all business of AccuRna will be succeeded by NanoCarrier. For detailed information, please refer to https://accurna.com/
[Contact Information]
CMIC HOLDINGS Co., Ltd. PR group
E-mail: pr@cmic.co.jp
AccuRna Inc.
https://accurna.com/contact-us/